Advertisement

Pharmaceutical Research

, Volume 34, Issue 10, pp 2142–2155 | Cite as

Evaluation of the Crystallization Tendency of Commercially Available Amorphous Tacrolimus Formulations Exposed to Different Stress Conditions

  • Niraj S. Trasi
  • Hitesh S. Purohit
  • Lynne S. TaylorEmail author
Research Paper

Abstract

Purpose

Tacrolimus, an immunosuppressant, is a poorly water soluble compound whereby the commercially available capsule formulations contain the drug in amorphous form. The goal of this study was to evaluate the robustness of the innovator product and five generic formulations to crystallization following storage at stress conditions.

Methods

Products were purchased from a pharmacy and stored at 40°C/75% relative humidity (RH), open dish conditions. Crystallinity was determined using X-ray diffraction. The quantity of the ingredients in the formulations were determined using different approaches and the various factors that might cause instability in the formulations were studied.

Results

After 4 weeks of open dish storage at 40°C/75% RH, one of the generic formulations showed evidence of tacrolimus crystallization. Further investigations revealed batch-to-batch variations in crystallization tendency with the extent of crystallinity varying between 50 and 100% for different batches. Crystallization was also observed at lower storage temperatures (30°C) when the RH was maintained at 75%. It was found that crystallization could be induced in a model formulation by wet granulating an ethanolic solution of the drug with lactose and drying at 60–70°C followed by exposure to stress conditions.

Conclusions

It seems probable that the generic that was susceptible to crystallization contains amorphous drug physically mixed with polymeric excipients, rather than as an amorphous solid dispersion. This study highlights the importance of considering the manufacturing process on the stability of the resultant amorphous product.

Key Words

amorphous crystallization generic stability tacrolimus 

Abbreviations

CCS

Cros-carmellose sodium

DSC

Differential scanning calorimetry

H-bond

Hydrogen bond

HPMC

Hydroxypropyl methylcellulose

HPMCAS

Hydroxypropylmethyl cellulose acetate succinate

MH

Monohydrate

MQ

Melt quenched

PVP

Polyvinylpyrrolidone

PVPVA

Polyvinylpyrrolidone-vinyl acetate

RH

Relative humidity

SEM

Scanning electron microscopy

UV

Ultraviolet

XRPD

X-ray powder diffraction

Notes

Acknowledgments and Disclosures

The authors acknowledge the U.S. Food And Drug Administration for financial support under grant award 1U01FD005259–01. The authors would like to acknowledge Dr. Dajun Sun and Dr. Hong Wen of the FDA for helpful discussions. Ms. Chailu Que is thanked for assistance with the SEM images. This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357. Dr. Byeongdu Lee (beamline 12-ID-B, Proposal GUP#43533, Advanced Photon Source, Argonne, Illinois) is acknowledged for his help with the X-ray measurements.

References

  1. 1.
    Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Solubility Advantage Of Amorphous Pharmaceuticals: I. A Thermodynamic Analysis J Pharm Sci. 2010;99(3):1254–64.PubMedGoogle Scholar
  2. 2.
    Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997;86(1):1–12.CrossRefPubMedGoogle Scholar
  3. 3.
    Qian F, Huang J, Hussain MA. Drug–polymer solubility and miscibility: stability consideration and practical challenges in amorphous solid dispersion development. J Pharm Sci. 2010;99(7):2941–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Kestur US, Taylor LS. Role of polymer chemistry in influencing crystal growth rates from amorphous felodipine. CrystEngComm. 2010;12(8):2390–7.CrossRefGoogle Scholar
  5. 5.
    Bhattacharya S, Suryanarayanan R. Molecular Motions In Sucrose-Pvp And Sucrose-Sorbitol Dispersions: I. Implications of Global and Local Mobility on Stability. Pharm Res. 2011;28(9):2191–203.CrossRefPubMedGoogle Scholar
  6. 6.
    Myerson AS, Gunde R. Crystals, crystal growth and nucleation. In: Myerson AS, editor. Handbook of industrial crystallization. Butterworth-Heinemann; 2002. P. 33–65.Google Scholar
  7. 7.
    Trasi NS, Taylor LS. Effect of polymers on nucleation and crystal growth of amorphous acetaminophen. CrystEngComm. 2012;14(16):5188–97.CrossRefGoogle Scholar
  8. 8.
    Mosquera-Giraldo LI, Trasi NS, Taylor LS. Impact of surfactants on the crystal growth of amorphous celecoxib. Int J Pharm. 2014;461(1–2):251–257.Google Scholar
  9. 9.
    Zhang SW, Yu L, Huang J, Hussain MA, Derdour L, Qian F, et al. A Method to evaluate the effect of contact with excipients on the surface crystallization of amorphous drugs. AAPS PharmSciTech. 2014;15(6):1516–26.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Karmwar P, Graeser K, Gordon KC, Strachan CJ, Rades T. Investigation of properties and recrystallisation behaviour of amorphous indomethacin samples prepared by different methods. Int J Pharm. 2011;417(1–2):94–100.CrossRefPubMedGoogle Scholar
  11. 11.
    Yang Z, Nollenberger K, Albers J, Moffat J, Craig D, Qi S. The effect of processing on the surface physical stability of amorphous solid dispersions. Eur J Pharm Biopharm. 2014;88(3):897–908.CrossRefPubMedGoogle Scholar
  12. 12.
    Ahlneck C, Zografi G. The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state. Int J Pharm. 1990;62(2–3):87–95.CrossRefGoogle Scholar
  13. 13.
    Tian B, Zhang L, Pan Z, Gou J, Zhang Y, Tang X. A comparison of the effect of temperature and moisture on the solid dispersions: Aging and crystallization. Int J Pharm. 2014;475(1–2):385–92.CrossRefPubMedGoogle Scholar
  14. 14.
    Purohit HS, Taylor LS. Phase separation kinetics in amorphous solid dispersions upon exposure to water. Mol Pharm. 2015;12(5):1623–35.CrossRefPubMedGoogle Scholar
  15. 15.
    Marsac PJ, Konno H, Taylor LS. A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm Res. 2006;23(10):2306–16.CrossRefPubMedGoogle Scholar
  16. 16.
    Yu L, Reutzel-Edens SM, Mitchell CA. Crystallization and polymorphism of conformationally flexible molecules: problems, patterns, and strategies. Org Process Res Dev. 2000;4(5):396–402.Google Scholar
  17. 17.
    Zhou D, Zhang GGZ, Law D, Grant DJW, Schmitt EA. Physical stability of amorphous pharmaceuticals: importance of configurational thermodynamic quantities and molecular mobility. J Pharm Sci. 2002;91(8):1863–72.CrossRefPubMedGoogle Scholar
  18. 18.
    Trasi NS, Baird JA, Kestur US, Taylor LS. Factors influencing crystal growth rates from undercooled liquids of pharmaceutical compounds. J Phys Chem B. 2014;118(33):9974–82.CrossRefPubMedGoogle Scholar
  19. 19.
    Graeser KA, Patterson JE, Zeitler JA, Gordon KC, Rades T. Correlating thermodynamic and kinetic parameters with amorphous stability. Eur J Pharm Sci. 2009;37(3–4):492–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Tang XLC, Pikal MJ, Taylor LS. A spectroscopic investigation of hydrogen bond patterns in crystalline and amorphous phases in dihydropyridine calcium channel blockers. Pharm Res. 2002;19(4):477–83.CrossRefPubMedGoogle Scholar
  21. 21.
  22. 22.
    Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29(6):404–30.CrossRefPubMedGoogle Scholar
  23. 23.
    Ensor C, Trofe-Clark J, Gabardi S, Mcdevitt-Potter LM, Shullo MA. Generic maintenance immunosuppression in solid organ transplant recipients. Pharmacotherapy. 2011;31(11):1111–29.CrossRefPubMedGoogle Scholar
  24. 24.
    Dubois M, Gilles KA, Hamilton JK, Rebers PA, Smith F. Colorimetric method for determination of sugars and related substances. Anal Chem. 1956;28(3):350–6.CrossRefGoogle Scholar
  25. 25.
    Trasi NS, Purohit HS, Wen H, Sun DD, Taylor LS. Non-sink dissolution behavior and solubility limit of commercial tacrolimus amorphous formulations. J Pharm Sci. 2017;106(1):264–72.CrossRefPubMedGoogle Scholar
  26. 26.
    Trasi NS, Boerrigter SXM, Byrn SR. Investigation of the milling-induced thermal behavior of crystalline and amorphous griseofulvin. Pharm Res. 2010;27(7):1377–89.CrossRefPubMedGoogle Scholar
  27. 27.
    Yamashita K, Nakate T, Okimoto K, Ohike A, Tokunaga Y, Ibuki R, et al. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm. 2003;267(1–2):79–91.CrossRefPubMedGoogle Scholar
  28. 28.
    Willart JF, Descamps M. Solid state amorphization of pharmaceuticals. Mol Pharm. 2008;5(6):905–20.CrossRefPubMedGoogle Scholar
  29. 29.
    Wanapun D, Kestur US, Taylor LS, Simpson GJ. Single particle nonlinear optical imaging of trace crystallinity in an organic powder. Anal Chem. 2011;83(12):4745–51.CrossRefPubMedGoogle Scholar
  30. 30.
    Public Assessment Report of the Medicines Evaluation Board in the Netherlands,Tacrolimus Intas 5 mg capsules, hard, Intas Pharmaceuticals Limited, United Kingdom. 2016. Available from: http:\\db.cbg-meb.nl/pars/h108987.pdf. [website].Google Scholar
  31. 31.
    Mesnier X, Althaus to, Forny L, Niederreiter G, Palzer S, Hounslow MJ, et al. A novel method to quantify tablet disintegration. Powder Technol. 2013;238:27–34.CrossRefGoogle Scholar
  32. 32.
    Honbo T, Kobayashi M, Hane K, Ueda Y. The oral dosage form of fk-506. Transplant Proc. 1987;19:17–22.PubMedGoogle Scholar
  33. 33.
    Burnett DJ, Thielmann F, Booth J. Determining the critical relative humidity for moisture-induced phase transitions. Int J Pharm. 2004;287(1–2):123–33.CrossRefPubMedGoogle Scholar
  34. 34.
    Gordon MS, Chatterjee B, Chowhan ZT. Effect of the mode of croscarmellose sodium incorporation on tablet dissolution and friability. J Pharm Sci. 1990;79(1):43–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Lopez-Solis J, Villafuerte-Robles L. Effect of disintegrants with different hygroscopicity on dissolution of norfloxacin/pharmatose dcl 11 tablets. Int J Pharm. 2001;216(1–2):127–35.CrossRefPubMedGoogle Scholar
  36. 36.
    Taylor LS, Zografi G. Spectroscopic characterization of interactions between pvp and indomethacin in amorphous molecular dispersions. Pharm Res. 1997;14(12):1691–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Crowley KJ, Zografi G. Cryogenic grinding of indomethacin polymorphs and solvates: assessment of amorphous phase formation and amorphous phase physical stability. J Pharm Sci 2002;91(2):492–507.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Department of Industrial and Physical Pharmacy, College of PharmacyPurdue UniversityWest LafayetteUSA

Personalised recommendations